Research
Hormonal
Glucagon-like peptide-1 (GLP-1) agonists lead to greater weight loss in clinical trials and real-world settings than orlistat.
GLP-1 agonists may be a more effective pharmacological option for weight management in patients with obesity and inflammatory skin conditions.
StrongSupportsmedium confidence
These drugs have led to greater weight loss in clinical trials and real-world settings than orlistat.
Why this rating
The claim is based on clinical trials and real-world evidence.
Source
[Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases
Eva Vilarrasa et al. · Actas Dermo-Sifiliográficas · 2023
reviewCited 5×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →